McDonald’s is essentially preparing for the future where weight-loss pills make people eat less, and the Golden Arches is positioning protein-heavy menu items as the solution. CEO Chris Kempczinski acknowledged on an earnings call Wednesday that GLP-1 weight-loss drugs are seeing strong adoption, especially now that the pill form (Novo Nordisk’s Wegovy) arrived at pharmacies in early January and Eli Lilly’s version is expected soon. He’s not panicking yet—McDonald’s saw no material impact on business in the fourth quarter but he’s also not naive about what happens when millions of Americans start taking appetite-suppressing medications.
Here’s what Kempczinski knows that should concern every fast-food chain: when GLP-1 consumers eat, they consume fewer calories, but more importantly, they change the mix of what they eat. “We know that consumers’ behavior changes,” he said on the call. “We know that in general, they eat fewer calories in the day, but also what they eat, the mix of that changes. Fortunately, for us, protein is one of the areas that the GLP-1 consumer is still very much interested in, and we’ve got a great protein offering on our menu.”
Translation: McDonald’s is betting that when weight-loss pill users come to the restaurant, they’ll choose chicken sandwiches and protein-focused items over Big Macs and fries. That’s a strategic shift. McDonald’s is essentially testing new menu items likely chicken tenders based on Kempczinski’s comments specifically designed to capture the GLP-1 consumer who wants to eat something but in smaller portions with higher protein.
The timeline matters here because the pill form changes everything about adoption rates. Wegovy injections required weekly shots, which created a barrier to entry. The pill form removes that friction. Factor in the Trump administration’s push to bring down weight-loss drug prices, and suddenly millions of Americans who couldn’t access or couldn’t afford GLP-1s now can. That’s not a niche market anymore that’s a massive demographic shift in consumer behavior.
McDonald’s isn’t the only Big Food player watching nervously
PepsiCo CEO Ramon Laguarta said on Yahoo Finance that the company is “leaning into portion control” because consumers are “continuing to engage in our categories, but in smaller portions.” They want their favorite products, just less of them. That’s why PepsiCo is betting on multipack strategies smaller portions that align with how GLP-1 consumers actually eat.
What’s interesting is that McDonald’s isn’t acting defeated
They’re acting strategic. They didn’t sit around waiting to see if GLP-1s would impact business. Kempczinski is monitoring snacking habit changes, testing less-sugary beverages, and experimenting with menu items designed for the GLP-1 era. That’s forward-thinking rather than reactive positioning.
The business evidence backs up McDonald’s confidence
In the fourth quarter, McDonald’s reported quarterly earnings and sales that beat analyst estimates. Same-store sales rose 5.7% when analysts expected 3.9% growth. Their McValue menu brought customers back. They’re not suffering under the weight-loss pill wave yet. But management is clearly preparing for the moment when adoption becomes so widespread that casual diners shift their habits.
The real battle isn’t Big Mac versus Ozempic
It’s about which chains adapt menu offerings to the GLP-1 reality and which ones ignore it. McDonald’s is choosing to adapt by positioning protein as the answer. Whether that strategy works depends on whether GLP-1 consumers will actually choose McDonald’s chicken sandwiches over competitors’ offerings or whether they’ll just eat less overall and skip fast food entirely.
That’s the real question keeping Kempczinski up at night.
